Last updated: August 11, 2026
Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, No. 1:17-cv-01131, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Alvogen's proposed generic version of OxyContin, Purdue's abuse-deterrent extended-release oxycodone product. Purdue asserted patents covering the product's abuse-deterrent formulation. The case ended without a reported merits decision, claim-construction ruling, or trial judgment.
What drug and ANDA were at issue in Purdue Pharma v. Alvogen?
The litigation concerned oxycodone hydrochloride extended-release tablets, the active pharmaceutical ingredient in OxyContin.
Alvogen filed an abbreviated new drug application seeking FDA approval for generic extended-release oxycodone tablets. Purdue treated the ANDA filing as an act of infringement under 35 U.S.C. § 271(e)(2), based on Alvogen's Paragraph IV positions against Purdue's listed patents.
| Item |
Case information |
| Brand product |
OxyContin |
| Active ingredient |
Oxycodone hydrochloride |
| Dosage form |
Extended-release oral tablets |
| Therapeutic category |
Opioid analgesic |
| Plaintiff |
Purdue Pharma L.P. |
| Defendant |
Alvogen Pine Brook, LLC |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:17-cv-01131 |
| Litigation type |
Hatch-Waxman ANDA patent litigation |
| Regulatory pathway |
ANDA with Paragraph IV allegations |
| Reported outcome |
Disposition without a merits trial or published validity ruling |
The relevant product used a controlled-release formulation designed to resist crushing and other forms of manipulation associated with opioid abuse. Purdue's infringement theory therefore focused on formulation and dosage-form limitations rather than only on oxycodone as an active ingredient.
What patents protected OxyContin in the Alvogen litigation?
Purdue's OxyContin patent estate included patents directed to abuse-deterrent controlled-release dosage forms. The patents associated with this litigation and the broader OxyContin patent estate included the following:
| Patent |
General subject matter |
Relevance |
| U.S. Patent No. 8,337,888 |
Abuse-deterrent controlled-release dosage forms |
Core formulation protection |
| U.S. Patent No. 8,808,729 |
Abuse-deterrent controlled-release dosage forms |
Continuation-related formulation claims |
| U.S. Patent No. 9,161,920 |
Abuse-deterrent opioid dosage forms |
Product and formulation protection |
| U.S. Patent No. 9,693,961 |
Abuse-deterrent controlled-release dosage forms |
Later-issued continuation protection |
| U.S. Patent No. 9,763,880 |
Abuse-deterrent dosage-form technology |
Additional formulation claims |
| U.S. Patent No. 9,775,838 |
Abuse-deterrent dosage-form technology |
Additional listed protection |
The exact patent set asserted against an ANDA depends on the complaint, amended pleadings, and the patents listed in the FDA's Orange Book at the time of the ANDA filing. Purdue's litigation strategy generally relied on multiple overlapping formulation patents to increase the number of infringement theories and preserve the possibility of a 30-month FDA approval stay.
What formulations were protected?
The OxyContin patents generally addressed combinations of:
- Oxycodone or an oxycodone salt;
- A controlled-release matrix;
- Water-swellable or gelling components;
- High drug loading;
- Physical characteristics that made crushing, grinding, or extraction more difficult;
- Release profiles designed for extended oral administration.
The commercial value of the estate was tied to the finished dosage form. A generic applicant could avoid infringement by changing excipients, drug loading, matrix architecture, release characteristics, or manufacturing parameters, but those changes could create separate bioequivalence or product-development problems.
What was the procedural history of the case?
Purdue filed the action in 2017 after Alvogen's ANDA filing. The complaint triggered the Hatch-Waxman litigation framework and the statutory stay on FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the limitations of that provision.
The publicly reported record does not show a final judgment following a bench trial. The action was resolved through a negotiated disposition rather than through a published ruling on:
- Patent validity;
- Claim construction;
- Infringement;
- Obviousness;
- Written description;
- Enablement;
- The scope of the abuse-deterrent claims.
That outcome limits the case's precedential value. It does not establish that Alvogen's proposed product infringed, nor does it establish that Purdue's patents would have survived invalidity challenges.
Was there a Paragraph IV challenge to Purdue's OxyContin patents?
Yes. The case arose from Alvogen's ANDA and Purdue's response to Paragraph IV allegations. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.
Paragraph IV litigation creates two simultaneous risks for the parties:
- The patent holder may obtain a judgment blocking approval until patent expiration.
- The generic applicant may obtain a first-filer or litigation advantage if it prevails or reaches a settlement with an early entry date.
The record does not show a reported final Paragraph IV decision in Alvogen's favor. The absence of a merits ruling means the case cannot be used as authority for the validity or enforceability of the OxyContin formulation patents.
What was the Orange Book status of OxyContin?
OxyContin was listed in the FDA Orange Book with patents directed to its extended-release, abuse-deterrent formulation. The Orange Book listings were central to the litigation because they provided the statutory basis for Alvogen's Paragraph IV certifications and Purdue's infringement action.
The listed patents were composition-of-matter or formulation patents rather than method-of-use patents directed to a particular disease indication. That distinction matters because a generic applicant may sometimes avoid method-of-use patent infringement through a section viii labeling carve-out. A formulation patent generally cannot be carved out if the proposed product itself embodies the claimed formulation.
The Orange Book-listed patent estate did not create perpetual exclusivity. The principal OxyContin formulation patents were scheduled to expire around 2025, subject to patent-term adjustment, pediatric exclusivity, terminal disclaimers, and the specific expiration date for each patent. Expiration of one patent did not necessarily eliminate all barriers if other listed patents remained enforceable.
When did Purdue's OxyContin patents lose exclusivity?
The principal OxyContin formulation patents had expiration dates concentrated around 2025. The operative commercial date depended on:
- The expiration date of each listed patent;
- Any available six-month pediatric extension;
- FDA approval timing;
- Whether a generic applicant obtained an earlier negotiated entry right;
- Whether other patents or regulatory exclusivities remained in effect.
The patents did not provide biologic-style exclusivity. OxyContin is a small-molecule drug, so biosimilar rules do not apply. Generic competition proceeds through the ANDA pathway, not through the Biologics Price Competition and Innovation Act pathway.
Did pediatric exclusivity extend OxyContin protection?
Any pediatric exclusivity associated with the product would extend applicable exclusivity periods for six months, but it would not independently create a new patent. Pediatric exclusivity also does not automatically extend every patent in the product's history. The effect must be determined against the specific patents and regulatory exclusivities listed in FDA records.
Did Alvogen obtain a license or settlement entry date?
The case ended through a negotiated resolution. Public docket materials establish the disposition but do not provide a reported merits judgment. Settlement terms in pharmaceutical patent cases may address:
- A permitted generic launch date;
- An authorized-generic arrangement;
- A license to Purdue's patents;
- Restrictions on launch before patent expiration;
- Dismissal of infringement claims;
- Allocation of litigation costs.
A docket dismissal alone does not disclose the economic terms of a confidential settlement. No public trial opinion establishes that Alvogen was licensed to launch immediately or that Purdue granted a broad license covering all OxyContin-related patents.
What litigation risks did Purdue's patent estate present?
Purdue's estate had moderate structural strength but meaningful invalidity and design-around risks.
Strengths
The patents covered a commercial product with a defined physical formulation. Product claims can be easier to enforce than method-of-use claims when the generic tablet necessarily contains the claimed ingredients and release characteristics. Multiple continuation patents also increased the number of asserted claim sets.
The abuse-deterrence technology had commercial and regulatory relevance because Purdue marketed OxyContin as having abuse-deterrent properties recognized in FDA labeling. That positioning supported the commercial importance of the formulation claims, although FDA recognition does not establish patent validity.
Weaknesses
The estate faced conventional pharmaceutical patent defenses:
- Obviousness based on earlier controlled-release opioid systems;
- Lack of written description for broad formulation claims;
- Enablement challenges;
- Claim-construction disputes over excipient ranges and release properties;
- Noninfringement through formulation changes;
- Terminal-disclaimer limitations;
- Patent-term expiration concentrated near the expected generic-entry period.
The principal strategic issue was timing. If the patents survived long enough to reach their scheduled expiration, Alvogen's commercial upside from a settlement license could be limited. If Purdue obtained a favorable judgment before expiration, the stay on FDA approval and an injunction risk could protect remaining branded revenue.
What generic launch scenarios existed for Alvogen?
Three outcomes were commercially plausible:
| Scenario |
Effect on Alvogen |
Effect on Purdue |
| Purdue wins on validity and infringement |
FDA approval delayed until patent expiration or settlement license |
Preserves remaining OxyContin exclusivity |
| Alvogen wins on invalidity or noninfringement |
Potential launch before patent expiration |
Rapid erosion of branded sales |
| Settlement with licensed entry |
Launch on negotiated date and terms |
Converts litigation risk into controlled generic competition |
The settlement outcome removed the binary trial risk. It also prevented the case from producing a public decision that could have affected Purdue's broader OxyContin litigation program.
How did this case compare with other OxyContin generic litigation?
The Alvogen case was part of a broader patent-defense campaign involving generic manufacturers seeking approval for abuse-deterrent oxycodone products. Purdue pursued similar theories against multiple ANDA filers.
The common litigation issues were:
- Whether the generic formulation met the claimed abuse-deterrent limitations;
- Whether the formulation claims were obvious;
- Whether Purdue's continuation patents were subject to terminal disclaimers;
- Whether a generic could design around the claims while remaining bioequivalent;
- Whether settlement could preserve a delayed but commercially viable generic launch.
Unlike biologic patent disputes, these cases did not involve biosimilar interchangeability, the patent dance, or 12-year reference-product exclusivity. They were conventional small-molecule ANDA cases centered on listed formulation patents.
What is the current litigation significance of Purdue Pharma v. Alvogen?
The case has limited value as a legal precedent because it did not produce a reported claim-construction, validity, infringement, or appellate decision. Its commercial significance is greater than its doctrinal significance.
The case illustrates Purdue's strategy of using overlapping abuse-deterrent formulation patents to delay or negotiate generic entry. It also shows the limits of that strategy: when patent expiration is concentrated within a narrow period, a generic applicant may have leverage to secure a license or launch right without accepting a final infringement judgment.
Key Takeaways
- Purdue Pharma sued Alvogen Pine Brook in Delaware over an ANDA for generic extended-release oxycodone tablets.
- The dispute involved OxyContin's abuse-deterrent controlled-release formulation.
- Purdue relied on a portfolio that included U.S. Patent Nos. 8,337,888, 8,808,729, 9,161,920, and 9,693,961, among related patents.
- The case involved Paragraph IV allegations under the Hatch-Waxman Act.
- No reported merits judgment established infringement or patent validity.
- The action ended through a negotiated disposition.
- The principal formulation patents had expiration dates concentrated around 2025, subject to patent-specific adjustments and applicable exclusivity.
- Biosimilar risk was irrelevant because oxycodone is a small-molecule drug.
- The case's principal business significance was generic-entry timing, not creation of new patent precedent.
FAQs About Purdue Pharma v. Alvogen Pine Brook
Was Alvogen found to infringe Purdue's OxyContin patents?
No reported decision in the case found Alvogen liable for infringement. The action ended without a publicly reported merits judgment.
Did the case involve OxyContin's opioid active ingredient or its abuse-deterrent technology?
The dispute centered on the extended-release abuse-deterrent dosage form. Purdue's claims were directed primarily to formulation and release characteristics rather than a novel oxycodone molecule.
Could Alvogen launch generic OxyContin before all Purdue patents expired?
Only if permitted by a settlement license, a favorable court decision, or expiration of the relevant patents. FDA approval could remain subject to the Hatch-Waxman stay and listed-patent restrictions.
Were Purdue's OxyContin patents method-of-use patents?
The patents relevant to this litigation were primarily formulation and dosage-form patents. That limited the usefulness of a section viii labeling carve-out.
Does this case affect current generic oxycodone competition?
The case provides historical context for Purdue's OxyContin patent enforcement. Current market entry depends on the individual patent status, FDA approvals, settlement rights, and commercial status of each generic product.
References
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
-
U.S. District Court for the District of Delaware. (2017). Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, No. 1:17-cv-01131. PACER docket.
-
U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
-
U.S. Code. (2024). 21 U.S.C. § 355: New drugs. https://uscode.house.gov/
-
U.S. Code. (2024). 35 U.S.C. § 271: Infringement of patent. https://uscode.house.gov/
